{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"18.4","upperLimit":"90.1","value":"57.1"},{"groupId":"OG001","lowerLimit":"9.4","upperLimit":"99.2","value":"66.7"},{"groupId":"OG002","lowerLimit":"6.4","upperLimit":"47.6","value":"22.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"18"}],"units":"Participants"}],"description":"Overall response rate (ORR), including stringent complete response (sCR), complete response (CR), very good partial response (VGPR) and partial response (PR) according to the International Myeloma Working Group (IMWG) criteria","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients received plitidepsin 4 mg/m2 and BTZ 1 mg/m2 and DXM 40 mg. DXM was administered at least one hour before the start of plitidepsin infusion, and BTZ was administered one minute after the end of the plitidepsin infusion. Patients received a maximum of eight treatment cycles","id":"OG000","title":"Plitidepsin (4 mg/m2)+BTZ (1 mg/m2)+DXM (40 mg)"},{"description":"Patients received plitidepsin 4 mg/m2 and BTZ 1.3 mg/m2 and DXM 40 mg. DXM was administered at least one hour before the start of plitidepsin infusion, and BTZ was administered one minute after the end of the plitidepsin infusion. Patients received a maximum of eight treatment cycles","id":"OG001","title":"Plitidepsin (4 mg/m2)+BTZ (1.3 mg/m2)+DXM (40 mg)"},{"description":"Patients received plitidepsin 5 mg/m2 and BTZ 1.3 mg/m2 and DXM 40 mg. DXM was administered at least one hour before the start of plitidepsin infusion, and BTZ was administered one minute after the end of the plitidepsin infusion. Patients received a maximum of eight treatment cycles","id":"OG002","title":"Plitidepsin (5 mg/m2)+BTZ (1.3 mg/m2)+DXM (40 mg)"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"Response or disease progression was assessed on Day 1 of each cycle, assessed up to 4 years","title":"Overall Response Rate","type":"SECONDARY","unitOfMeasure":"percentage of participants"}